Zai Lab and Amgen will collaborate on a clinical trial to evaluate a Zai Lab lung cancer therapy.
Under the agreement, Amgen will sponsor a global phase 1b study to evaluate the safety and efficacy of Zai Lab's zoci drug in combination with Amgen's Imdelltra to treat extensive-stage small cell lung cancer.
Zai Lab will retain ownership of zoci, known generically as zocilurtatug pelitecan, and supply the drug for Amgen's trial.
"In combination, this dual-targeting strategy has the potential to increase the rate and deepen responses both systemically and, in the brain, address resistance pathways, and unlock new treatment paradigms for patients with small cell lung cancer," Zai Lab Head of Global Research and Development, Rafael Amado, said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.